1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Streptococcal Infections - Pipeline Review, H2 2013

Streptococcal Infections - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 69 pages

Streptococcal Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Streptococcal Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Streptococcal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Streptococcal Infections. Streptococcal Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Streptococcal Infections.
- A review of the Streptococcal Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Streptococcal Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Streptococcal Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Streptococcal Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Streptococcal Infections - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Streptococcal Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Streptococcal Infections 9
Streptococcal Infections Therapeutics under Development by Companies 11
Streptococcal Infections Therapeutics under Investigation by Universities/Institutes 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Streptococcal Infections Therapeutics - Products under Development by Companies 17
Streptococcal Infections Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Streptococcal Infections Therapeutics Development 19
Novartis AG 19
Wockhardt Limited 20
Hadasit Medical Research Services and Development Ltd 21
Intercell AG 22
Nymox Pharmaceutical Corporation 23
C3 Jian, Inc 24
Evolva SA 25
Viral Genetics, Inc. 26
Sequoia Sciences, Inc. 27
Ascenion GmbH 28
Trellis Bioscience, Inc. 29
Wellstat Vaccines, LLC 30
Streptococcal Infections - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
NXB-5886 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Group B Streptococcus Antibodies - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Group A Streptococcus Vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
AVX-13616 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Group B Streptococcus Vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Group A Streptococcus Peptide - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
CF-301 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
StrepNovA Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
VGV-S - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Second Generation Ketolides - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
EV-035 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
C-16G2 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Streptococcal Vaccines - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Group B Streptococci Vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Antibacterial Program - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Carolacton - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Group B Streptococcus Vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Synthetic Peptide Vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Group A Streptococcus Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Antibodies For Group A Streptococcus Infections - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Streptococcal Infections Therapeutics - Drug Profile Updates 58
Streptococcal Infections Therapeutics - Dormant Products 60
Streptococcal Infections - Product Development Milestones 61
Featured News and Press Releases 61
Mar 12, 2013: ImmBio Wins Funding From UK Government-backed Biomedical Catalyst To Develop Multi-strain Pneumococcal Vaccine 61
Dec 14, 2011: ContraFect Completes Successful Pre-IND Meeting With FDA 61
Mar 18, 2010: Genocea Biosciences Signs Exclusive License Agreement with Children's Hospital Boston for Novel Streptococcus Pneumoniae Antigens 62
Jul 28, 2009: Wyeth recalls lot of Prevnar vaccine. 62
Aug 26, 2008: FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections 63
Jun 25, 2008: IBT receives NIH grant 63
Mar 18, 2008: FDA Issues Approvable Letter For Ceftobiprole, A New Anti-MRSA Broad-Spectrum Antibiotic 64
Oct 04, 2007: Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease. 65
Jul 27, 2007: Wyeth Team Recognized by White House With Prestigious National Medal of Technology for PREVNAR Vaccine. 66
May 18, 2007: New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole 66
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Tables

Number of Products Under Development for Streptococcal Infections, H2 2013 9
Products under Development for Streptococcal Infections - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Clinical Stage Development, H2 2013 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 16
Products under Development by Companies, H2 2013 17
Products under Investigation by Universities/Institutes, H2 2013 18
Novartis AG, H2 2013 19
Wockhardt Limited, H2 2013 20
Hadasit Medical Research Services and Development Ltd, H2 2013 21
Intercell AG, H2 2013 22
Nymox Pharmaceutical Corporation, H2 2013 23
C3 Jian, Inc, H2 2013 24
Evolva SA, H2 2013 25
Viral Genetics, Inc., H2 2013 26
Sequoia Sciences, Inc., H2 2013 27
Ascenion GmbH, H2 2013 28
Trellis Bioscience, Inc., H2 2013 29
Wellstat Vaccines, LLC, H2 2013 30
Assessment by Monotherapy Products, H2 2013 31
Assessment by Stage and Route of Administration, H2 2013 33
Assessment by Stage and Molecule Type, H2 2013 35
Streptococcal Infections Therapeutics - Drug Profile Updates 58
Streptococcal Infections Therapeutics - Dormant Products 60

List of Figures

Number of Products under Development for Streptococcal Infections, H2 2013 9
Products under Development for Streptococcal Infections - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Mid Clinical Stage Products, H2 2013 14
Early Clinical Stage Products, H2 2013 15
Discovery and Pre-Clinical Stage Products, H2 2013 16
Assessment by Monotherapy Products, H2 2013 31
Assessment by Route of Administration, H2 2013 32
Assessment by Stage and Route of Administration, H2 2013 33
Assessment by Molecule Type, H2 2013 34
Assessment by Stage and Molecule Type, H2 2013 35

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.